Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 rearrange |
Therapy | Pembrolizumab |
Indication/Tumor Type | ovarian carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 rearrange | ovarian carcinoma | sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a clinical case study, a patient with high grade ovarian carcinoma harboring a CD274 rearrangement demonstrated a complete response when treated with Keytruda (pembrolizumab) (PMID: 29351920). | 29351920 |
PubMed Id | Reference Title | Details |
---|---|---|
(29351920) | Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. | Full reference... |